The cerebral hypometabolism identified by (18F)FDG PET is beneficial for disease identification and staging if recorded CSF biomarkers and regularly checked MMSE values are insufficiently decisive despite the lack of pathological specificity. Additionally, a multi-biomarker approach, such as detecting tau protein and Aβ amyloid in the CSF, PET FDG, and PET FBB, is beneficial for precise AD diagnosis. Here, MAPT is linked to Alzheimer disease.